Skip to main content
UniHealth

Doctor search

Meredith J Barad, MD

Neurology · Stanford

NPI 1568656353

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
10
2 carriers
Offices
3

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Research they published

62 papers · cited 809 times

Published as Meredith J. Barad at Stanford University, Stanford Medicine.

Research identity is not a guarantee of current clinical practice. Same name is not the same person — if this looks like someone else, tell us.

Most recent papers
2026A meta-analysis of pain intensity changes after placebo interventions in facial pain.PubMed
2026Don’t just fill to fill: thoughts on the 2026 match from the Association of Pain Program DirectorsFirst authorPain Medicine
2026Shrinking pipelines and shifting priorities: an analysis of the 2019-2025 pain medicine fellowship matchLast authorPain Medicine
2026Match Program Signaling in Pain Medicine Fellowship Applications: Association with Interview Outcomes and Implications for a Shrinking Applicant Pipeline.PubMed
2026Endoscopic transnasal sphenopalatine ganglion block for chronic craniofacial painEuropean Archives of Oto-Rhino-Laryngology
2026Debunking myths in facial pain diagnosis for the pain practitionerRegional Anesthesia & Pain Medicine
See the 37 most recent papers
Earlier papers
2025Beyond headache: non-cephalic pain, fatigue, and post-traumatic stress symptoms as longitudinal predictors of chronic migraine outcomesPain Medicine
2025Reaching international consensus on the definition of refractory migraine using the Delphi methodCephalalgia
2025Practice advisory for intravenous management of headache disorders in hospitalized patients: a review of the evidence and consensus recommendationsRegional Anesthesia & Pain Medicine
2025Chronic pain fellowships and emergency medicine residency: similarities and synergyPain Medicine
2024Enhancing early career development in pain medicine: the comprehensive role of mentorshipPain Medicine
2024Orofacial PainFirst authorCONTINUUM Lifelong Learning in Neurology
2024Current state of the pain medicine match: perspective and an eye to the futureRegional Anesthesia & Pain Medicine
2024Long-Term Epidural Patching Outcomes and Predictors of Benefit in Patients With Suspected CSF Leak Nonconforming to ICHD-3 CriteriaNeurology
2024Diagnosis and Treatment of Spontaneous Intracranial HypotensionNeurology Clinical Practice
2024Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trialsLast authorHeadache The Journal of Head and Face Pain
2024The current state of training in pain medicine fellowships: An Association of Pain Program Directors ( APPD ) survey of program directorsLast authorPain Practice
2023Pain Medicine Education in the United StatesLast authorAnesthesiology Clinics
2023Psychological Approaches for Migraine ManagementAnesthesiology Clinics
2023Pain Medicine Milestones 2.0: a step into the futurePain Medicine
2022The Molecular Basis and Pathophysiology of Trigeminal NeuralgiaInternational Journal of Molecular Sciences
2021Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working groupPain Medicine
2021Did she have an epidural? The long‐term consequences of postdural puncture headache and the role of unintended dural punctureFirst authorHeadache The Journal of Head and Face Pain
2021The Pain Medicine Fellowship Telehealth Education CollaborativePain Medicine
2021Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice GuidelineFirst authorPain Medicine
2021Chronic disabling postpartum headache after unintentional dural puncture during epidural anaesthesia: a prospective cohort studyBritish Journal of Anaesthesia
2021Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR studyFirst authorHeadache The Journal of Head and Face Pain
2020Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger ExposuresHeadache The Journal of Head and Face Pain
2020Diagnosis and management of chronic facial painLast authorBJA Education
2019Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread painFirst authorRegional Anesthesia & Pain Medicine
2018Correction to: Treatment Strategies for the Opioid-Dependent PatientLast authorCurrent Pain and Headache Reports
2017Treatment Strategies for the Opioid-Dependent PatientLast authorCurrent Pain and Headache Reports
2017Effect of Educating the Primary Care Physician About Headache to Help Reduce “Trivial” Referrals and Improve the Number and Quality of “Substantial” Referrals that Truly Need Subspecialty Headache Medicine CareLast authorCurrent Treatment Options in Neurology
2013Complex Regional Pain Syndrome Is Associated With Structural Abnormalities in Pain-Related Regions of the Human BrainFirst authorJournal of Pain
2011Human Response to Unintended Intrathecal Injection of Botulinum ToxinPain Medicine
2009Serratus muscle stimulation effectively treats notalgia paresthetica caused by long thoracic nerve dysfunction: a case seriesJournal of Brachial Plexus and Peripheral Nerve Injury
2001Xenopus p63 expression in early ectoderm and neurectodermMechanisms of Development

Topics: Migraine and Headache Studies · Temporomandibular Joint Disorders · Mental Health Treatment and Access · Anesthesia and Pain Management · Pain Mechanisms and Treatments

Plans that list them

10 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barad’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

10 of 10 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A88123 · Current

Licensed to practise in California · since 2004 · expires 2027-11-30 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$38,343

Medicare paid this office $38,343 for 181 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)111$18,470$111
New patient visit (60+ min)50$8,361$167
Long return visit (40+ min)46$7,779$156
Short return visit (20+ min)16$1,628$78
Administration of psychological or neuropsychological test, first 30 minutes11$430$39
See all 6 services
Every Original Medicare service billed
Return visit (30+ min)111$18,470$111
New patient visit (60+ min)50$8,361$167
Long return visit (40+ min)46$7,779$156
Short return visit (20+ min)16$1,628$78
Administration of psychological or neuropsychological test, first 30 minutes11$430$39
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's19$297$15

Who their Medicare patients are

181 Original Medicare patients in 2024. Average age 68 · Under 65 27% · Women 74% · Also on Medicaid 23% · Health risk score 1.18. At or below the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 55% · Depression 39% · Diabetes 19% · Coronary heart disease 17% · Chronic kidney disease 14% · Cancer 13% · Atrial fibrillation 12% · Stroke 12% · Heart failure 9% · COPD 9%.

The office billed $219,632, Medicare allowed $51,025 and paid $38,343; for 327 services of 7 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024181327681.18$219,632$38,343
2023179280691.23$198,959$25,824
2022164260681.19$177,131$24,494
2021161287671.39$199,131$27,803
2020151307641.38$156,659$23,920
2019168307641.21$83,363$24,252
2018172317641.22$113,989$26,379
2017157279651.28$107,832$22,399
2016192366651.29$216,348$29,121
2015193340651.38$175,034$27,765
2014189353641.26$184,411$29,542
2013170318611.49$140,502$26,249

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Return visit (30+ min)102$12,101$79
Long return visit (40+ min)41$5,493$125
New patient visit (60+ min)37$4,919$133
Short return visit (20+ min)11$540$45

2022: 5 services

Original Medicare services billed in 2022
Return visit (30+ min)78$9,199$82
Long return visit (40+ min)37$4,684$127
New patient visit (60+ min)28$3,698$132
Return visit (30+ min)18$2,266$81
Short return visit (20+ min)11$724$56

2021: 4 services

Original Medicare services billed in 2021
Return visit (30+ min)87$10,459$85
Long return visit (40+ min)43$5,624$120
New patient visit (60+ min)27$4,090$151
Return visit (30+ min)18$3,064$81

2020: 6 services

Original Medicare services billed in 2020
Return visit (30+ min)73$7,678$65
Long return visit (40+ min)29$2,903$97
New patient visit (60+ min)19$2,760$145
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face15$2,448$102
Return visit (30+ min)20$2,195$69
Short return visit (20+ min)23$1,154$43

2019: 6 services

Original Medicare services billed in 2019
Return visit (30+ min)78$6,817$64
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face29$3,964$94
Long return visit (40+ min)36$3,624$95
New patient visit (60+ min)21$3,018$144
Return visit (30+ min)14$1,579$69
New patient visit (45+ min)11$1,154$105

2018: 6 services

Original Medicare services billed in 2018
Return visit (30+ min)72$6,982$67
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face32$5,272$96
New patient visit (60+ min)32$4,649$145
New patient visit (45+ min)29$3,046$105
Long return visit (40+ min)26$2,655$98
Other procedure on nervous system11$234$15

2017: 6 services

Original Medicare services billed in 2017
Return visit (30+ min)68$6,814$67
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face24$4,367$102
New patient visit (60+ min)31$4,122$133
New patient visit (45+ min)25$2,764$111
Long return visit (40+ min)22$2,046$93
Other procedure on nervous system13$516$21

2016: 7 services

Original Medicare services billed in 2016
Return visit (30+ min)78$6,961$64
New patient visit (60+ min)35$4,724$135
New patient visit (45+ min)37$3,893$105
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face18$3,630$101
Long return visit (40+ min)15$1,487$99
Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes21$853$39
Short return visit (20+ min)15$746$44

2015: 8 services

Original Medicare services billed in 2015
Return visit (30+ min)77$7,328$67
New patient visit (60+ min)44$6,122$139
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face16$2,787$107
Other procedure on nervous system12$2,120$118
New patient visit (45+ min)15$1,734$116
Long return visit (40+ min)14$1,210$86
Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes19$679$36
Ultrasonic guidance for needle placement14$474$30

2014: 8 services

Original Medicare services billed in 2014
New patient visit (60+ min)59$8,590$146
Return visit (30+ min)74$7,089$67
Long return visit (40+ min)33$3,456$99
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face13$2,705$100
New patient visit (45+ min)12$1,389$116
Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes21$806$38
Short return visit (20+ min)14$546$39
Fluoroscopic guidance for spine or back muscle injection13$355$27

2013: 8 services

Original Medicare services billed in 2013
New patient visit (60+ min)48$6,658$139
Return visit (30+ min)52$5,555$63
Long return visit (40+ min)33$3,265$93
Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face18$2,550$111
New patient visit (45+ min)12$1,354$113
Short return visit (20+ min)20$791$40
Fluoroscopic guidance for spine or back muscle injection12$379$27
Ultrasonic guidance for needle placement11$317$29

Medicaid work

$357 in 2021

Medicaid paid $357 for 12 billed services this clinician did in 2021, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2021
Return visit (30+ min)12$357
Medicaid work by year
202112112$357

Drugs they prescribed that Part D paid

$207,018

Pharmacies billed $207,018 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 5% of their Part D prescriptions (45 of 911) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%. Long-acting opioids: 44% of their opioid prescriptions.

704 generic and 207 brand-name prescriptions · $207,018 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
EmgalityMigraine56$42,032$751
QuliptaNone23$28,230$1,227
Nurtec OdtNone11$20,467$1,861
ReyvowNone19$13,846$729
UbrelvyNone12$13,640$1,137
See all 27 drugs
Every Part D drug this clinician prescribed
EmgalityMigraine56$42,032$751
QuliptaNone23$28,230$1,227
Nurtec OdtNone11$20,467$1,861
ReyvowNone19$13,846$729
UbrelvyNone12$13,640$1,137
AjovyNone14$12,171$869
AimovigMigraine17$12,061$709
AjovyNone13$9,499$731
PregabalinNone69$2,497$36
DuloxetineNone72$1,714$24
OxcarbazepineNone28$922$33
GabapentinNone62$908$15
DivalproexNone24$868$36
NaratriptanNone23$707$31
RizatriptanNone31$560$18
Venlafaxine Hcl ErNone30$542$18
SumatriptanNone47$436$9
Ondansetron OdtNone12$374$31
MethadoneNone11$324$29
TopiramateNone28$295$11
NortriptylineNone12$278$23
OxycodoneNone13$203$16
Eletriptan HbrNone14$199$14
BaclofenNone11$145$13
AmitriptylineNone12$92$8
Butalbital-Acetaminophen-CaffeNone12$38$3
CyclobenzaprineNone11$28$3

Year by year

Part D prescribing by year
20249111495% (45)23%$207,018
20238881395% (42)22%$225,413
20228221204% (33)22%$233,421
20217391042% (16)19%$151,522
20209241106% (56)16%$153,158
20198601185% (46)16%$127,993
20187421084% (28)6%$59,598
20177741413% (19)12%$70,044
20166881305% (34)13%$68,039
20155551026% (33)None$53,873
20145811057% (42)17%$74,322
20135469619% (103)None$72,017

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 29 drugs

Part D drugs prescribed in 2023
EmgalityMigraine65$49,947$768
Nurtec OdtNone31$48,128$1,553
UbrelvyNone17$17,233$1,014
AimovigMigraine23$17,049$741
ReyvowNone21$16,563$789
SumatriptanNone11$3,692$336
GabapentinNone110$2,783$25
PregabalinNone21$1,989$95
SumatriptanNone29$1,836$63
DivalproexNone13$1,151$89
NaratriptanNone23$1,088$47
DuloxetineNone44$1,081$25
RizatriptanNone41$1,066$26
MemantineNone16$1,051$66
AcetazolamideNone11$994$90
OxcarbazepineNone18$897$50
Venlafaxine Hcl ErNone39$702$18
Carbamazepine ErNone15$582$39
MethadoneNone15$582$39
TopiramateNone32$487$15
PromethazineNone15$260$17
DiclofenacNone16$180$11
HydromorphoneNone12$168$14
OxycodoneNone12$134$11
BuprenorphineNone13$132$10
Prochlorperazine MaleateNone16$131$8
Ondansetron OdtNone13$101$8
TizanidineNone15$97$6
IbuprofenNone11$36$3

2022: 25 drugs

Part D drugs prescribed in 2022
Nurtec OdtNone63$88,738$1,409
EmgalityMigraine39$31,867$817
ReyvowNone34$24,381$717
UbrelvyNone13$13,831$1,064
AjovyNone14$10,039$717
SumatriptanNone39$4,495$115
SumatriptanNone15$4,022$268
PregabalinNone35$3,125$89
GabapentinNone71$2,273$32
DuloxetineNone23$2,249$98
OxcarbazepineNone18$1,921$107
NaratriptanNone19$1,628$86
RizatriptanNone35$1,077$31
MemantineNone26$973$37
LevetiracetamNone11$574$52
NortriptylineNone20$393$20
TopiramateNone47$351$7
PromethazineNone15$345$23
DiclofenacNone19$265$14
Venlafaxine Hcl ErNone22$244$11
OxycodoneNone13$171$13
BuprenorphineNone14$165$12
BaclofenNone17$164$10
TizanidineNone11$127$12
IbuprofenNone16$86$5

2021: 21 drugs

Part D drugs prescribed in 2021
Nurtec OdtNone31$39,010$1,258
UbrelvyNone20$20,167$1,008
AimovigMigraine19$15,157$798
AjovyNone16$11,103$694
EmgalityMigraine14$9,234$660
AjovyNone14$9,090$649
ReyvowNone11$7,645$695
PregabalinNone67$4,624$69
SumatriptanNone12$2,624$219
GabapentinNone64$1,547$24
OxcarbazepineNone26$1,469$57
DuloxetineNone33$1,408$43
NortriptylineNone32$680$21
PromethazineNone21$601$29
RizatriptanNone20$598$30
SumatriptanNone33$532$16
NaratriptanNone21$490$23
MemantineNone13$461$35
TopiramateNone24$299$12
Ondansetron OdtNone14$179$13
LamotrigineNone11$120$11

2020: 24 drugs

Part D drugs prescribed in 2020
AimovigMigraine44$35,424$805
PregabalinNone76$25,400$334
Nurtec OdtNone13$13,699$1,054
AjovyNone14$9,009$643
SumatriptanNone65$6,360$98
FrovatriptanNone19$5,255$277
GabapentinNone93$1,737$19
DuloxetineNone27$1,520$56
NaratriptanNone29$1,492$51
OxcarbazepineNone27$1,164$43
RizatriptanNone21$839$40
Candesartan CilexetilNone12$825$69
DiclofenacNone14$646$46
TopiramateNone43$582$14
Dextroamphetamine-AmphetamineNone12$526$44
NortriptylineNone29$475$16
AmitriptylineNone22$324$15
DoxepinNone12$262$22
PromethazineNone23$242$11
Divalproex Sodium ErNone11$203$18
OxycodoneNone19$193$10
ParoxetineNone15$158$11
CyclobenzaprineNone13$82$6
FurosemideNone11$34$3

2019: 23 drugs

Part D drugs prescribed in 2019
AimovigMigraine53$41,687$787
LyricaNone24$19,447$810
PregabalinNone26$2,079$80
GabapentinNone106$1,723$16
OxcarbazepineNone41$1,549$38
TopiramateNone56$1,321$24
NaratriptanNone26$1,272$49
DuloxetineNone27$1,189$44
SumatriptanNone53$1,011$19
DivalproexNone16$740$46
NortriptylineNone37$672$18
MemantineNone18$414$23
RizatriptanNone19$400$21
PromethazineNone37$355$10
DoxepinNone12$262$22
CarbamazepineNone16$223$14
PropranololNone11$220$20
Verapamil ErNone14$192$14
DiclofenacNone14$180$13
ModafinilNone11$141$13
OxycodoneNone16$118$7
CyclobenzaprineNone11$72$7
Ondansetron OdtNone11$69$6

2018: 22 drugs

Part D drugs prescribed in 2018
Lyrica23$19,349$841
Gabapentin95$2,426$26
Acetazolamide20$2,389$119
Naratriptan40$2,087$52
Duloxetine31$1,630$53
Oxcarbazepine35$1,593$46
Sumatriptan43$1,469$34
Topiramate54$1,212$22
Tramadol Hcl Er13$876$67
Rizatriptan27$872$32
Verapamil Er25$736$29
Nortriptyline35$705$20
Dextroamphetamine-Amphetamine11$573$52
Tizanidine13$291$22
Memantine14$259$18
Promethazine23$188$8
Cyclobenzaprine14$170$12
Baclofen19$167$9
Diclofenac13$134$10
Carbamazepine13$119$9
Oxycodone12$99$8
Ibu12$34$3

2017: 16 drugs

Part D drugs prescribed in 2017
Lyrica34$25,805$759
Duloxetine47$3,104$66
Gabapentin142$2,750$19
Naratriptan38$2,539$67
Acetazolamide20$2,122$106
Lidocaine18$1,563$87
Sumatriptan21$1,458$69
Rizatriptan28$1,402$50
Indomethacin Er11$1,125$102
Oxcarbazepine18$838$47
Tizanidine16$580$36
Topiramate26$490$19
Nortriptyline32$361$11
Promethazine22$263$12
Levothyroxine14$198$14
Carbamazepine12$21$2

2016: 16 drugs

Part D drugs prescribed in 2016
Lyrica47$28,543$607
Lidocaine28$5,736$205
Acetazolamide29$4,641$160
Gabapentin116$2,968$26
Duloxetine20$1,985$99
Rizatriptan38$1,289$34
Modafinil11$1,166$106
Mexiletine11$965$88
Tizanidine12$841$70
Sumatriptan26$840$32
Promethazine11$554$50
Topiramate43$441$10
Naratriptan13$378$29
Nortriptyline26$285$11
Baclofen11$233$21
Ibuprofen13$108$8

2015: 16 drugs

Part D drugs prescribed in 2015
Lyrica25$17,383$695
Lidocaine19$5,564$293
Duloxetine38$5,017$132
Gabapentin79$2,570$33
Rizatriptan18$1,027$57
Tizanidine16$836$52
Naratriptan15$692$46
Topiramate45$542$12
Baclofen16$452$28
Sumatriptan19$398$21
Venlafaxine Hcl Er17$263$15
Zolpidem18$208$12
Nortriptyline14$161$11
Ibuprofen14$130$9
Metoclopramide11$79$7
Mirtazapine12$57$5

2014: 17 drugs

Part D drugs prescribed in 2014
Lyrica31$17,181$554
Duloxetine30$12,127$404
Nuvigil11$5,727$521
Lidocaine33$3,219$98
Gabapentin77$2,766$36
Sumatriptan31$2,526$81
Diclofenac11$2,045$186
Tizanidine19$1,819$96
Venlafaxine Hcl Er19$1,061$56
Cyclobenzaprine18$864$48
Zonisamide13$444$34
Nortriptyline22$326$15
Topiramate22$294$13
Baclofen19$282$15
Zolpidem15$117$8
Ibuprofen11$99$9
Tramadol11$87$8

2013: 14 drugs

Part D drugs prescribed in 2013
Cymbalta44$19,275$438
Lyrica35$12,317$352
Rizatriptan17$3,922$231
Celebrex15$3,750$250
Gabapentin64$2,427$38
Sumatriptan22$1,696$77
Venlafaxine Hcl Er25$979$39
Zonisamide13$736$57
Topiramate15$510$34
Propranolol11$414$38
Hydrocodone-Acetaminophen18$253$14
Methadone24$251$10
Nortriptyline14$192$14
Zolpidem11$64$6

Money from drug and device companies

$375 in 2025

Industry payments by year
202511$375$375
202423$875$916
202323None$110
202244$1,500$1,557

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Merck Sharp & DohmeNone$375
1 payment
  • Consulting · 2025-11-24 · $375
See the published payment
Every published payment
Merck Sharp & DohmeConsulting · 2025-11-24None$375
See earlier years (2024, 2023, 2022)

2024: $916

Payments by company in 2024
Merck Sharp & DohmeNone$875
2 payments
  • Consulting · 2024-09-09 · $500
  • Consulting · 2024-08-26 · $375
Teva Pharmaceuticals USANone$41
1 payment
  • Meals · 2024-11-15 · $41

2023: $110

Payments by company in 2023
Impel PharmaceuticalsTrudhesa$69
2 payments
  • Meals for Trudhesa · 2023-11-16 · $43
  • Meals for Trudhesa · 2023-11-16 · $26
Teva Pharmaceuticals USAAjovy$41
1 payment
  • Meals for Ajovy · 2023-11-16 · $41

2022: $1,557

Payments by company in 2022
SPR TherapeuticsSprint Pns System$1,000
1 payment
  • Consulting for Sprint Pns System · 2022-12-31 · $1,000
NeuroMetrixNone$500
1 payment
  • Consulting · 2022-10-26 · $500
Impel PharmaceuticalsTrudhesa$55
1 payment
  • Meals for Trudhesa · 2022-04-01 · $55
GRT US HoldingQutenza$2
1 payment
  • Meals for Qutenza · 2022-03-19 · $2

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1568656353
Licence
CA A88123California A88123: Current · expires 2027-11-30
Trained
Stanford University School of Medicine, 2003
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 2084P2900X (2084P2900X); Neurology (2084N0400X)
Mailing address
Stanford University Medical Center, Pain Management Clinic, 300 Pasteur Dr., Rm A408, Stanford, CA, 94305
NPI first listed
2007-09-05
NPI last updated
2024-04-08
NPI record certified
2024-04-08

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: Stanford University Medical Center, Stanford, CA, 94305